晚期卵巢癌新辅助化疗的研究进展
Research Progress of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
摘要: 新辅助化疗在晚期卵巢癌患者的临床治疗中具有重要作用，由于新辅助化疗可缩小肿瘤病灶范围，以减少手术的难度，为手术达到满意减瘤创造条件，且术后并发症发生率低，住院时间缩短，故新辅助化疗已逐渐成为患者能接受的一线治疗方案。但其实施前的评估、最佳化疗周期、最佳IDS实施时机、联合靶向治疗效果、铂耐药及预后问题还存在诸多争议及不确定因素，需进行更多的科学研究，明确进行新辅助化疗的可行性及安全性，为患者的临床治疗提供可靠的依据，改善患者生存预后。
Abstract: Neoadjuvant chemotherapy plays an important role in the clinical treatment of patients with ad-vanced ovarian cancer. Because neoadjuvant chemotherapy can reduce the scope of tumor lesions, reduce the difficulty of surgery, and create conditions for satisfactory tumor reduction, with low incidence of postoperative complications and shorter hospital stay, neoadjuvant chemotherapy has gradually become the first-line treatment for patients. However, there are still many controversies and uncertain factors in the evaluation before implementation, the best chemotherapy cycle, the best implementation time of IDS, the effect of combined targeted therapy, platinum resistance and prognosis. More scientific research is needed to clarify the feasibility and safety of neoadjuvant chemotherapy, so as to provide reliable basis for the clinical treatment of patients and improve the survival and prognosis of patients.
文章引用：太吾斯耶·阿不都拉, 阿比达·阿布都卡德尔. 晚期卵巢癌新辅助化疗的研究进展[J]. 临床医学进展, 2024, 14(2): 3648-3655. https://doi.org/10.12677/ACM.2024.142509

参考文献

[1] Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2021) Cancer Statistics for the Year 2020: An Overview. Interna-tional Journal of Cancer, 149, 778-789. [Google Scholar] [CrossRef] [PubMed]
[2] Kessous, R., Laskov, I., Abitbol, J., et al. (2017) Clinical Outcome of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Gynecologic Oncology, 144, 474-479. [Google Scholar] [CrossRef] [PubMed]
[3] Fagotti, A., Ferrandina, G., Vizzielli, G., et al. (2016) Phase III Randomised Clinical Trial Comparing Primary Surgery versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer with High Tumour Load (SCORPION Trial): Final Analysis of Peri-Operative Outcome. European Journal of Cancer, 59, 22-33. [Google Scholar] [CrossRef] [PubMed]
[4] Kehoe, S., Hook, J., Nankivell, M., et al. (2015) Primary Chemo-therapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Ran-domised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. [Google Scholar] [CrossRef] 
[5] 王登凤, 张国楠, 彭春蓉, 等. 晚期卵巢上皮性癌患者NACT+IDS治疗模式的预后获益及影响因素分析[J]. 中华妇产科杂志, 2021, 56(6): 385-392.
[6] Melamed, A., Hinchcliff, E.M., Clemmer, J.T., et al. (2016) Trends in the Use of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer in the United States. Gynecologic Oncology, 143, 236-240. [Google Scholar] [CrossRef] [PubMed]
[7] 张静柳, 黄俊, 吴歆华. CT联合CA125检测在卵巢癌诊断中的应用价值[J]. 实用癌症杂志, 2015, 30(9): 1290- 1292.
[8] Phillips, A., Singh, K., Pounds, R., et al. (2017) Pre-dictive Value of the Age-Adjusted Charlston Co-Morbidity Index on Peri-Operative Complications, Adjuvant Chemo-therapy Usage and Survival in Patients Undergoing Debulking Surgery after Neo-Adjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer. Journal of Obstetrics and Gynaecology, 37, 1070-1075. [Google Scholar] [CrossRef] [PubMed]
[9] Suidan, R.S., Ramirez, P.T., Sarasohn, D.M., et al. (2017) A Multicenter Assessment of the Ability of Preoperative Computed Tomography Scan and CA-125 to Predict Gross Residual Disease at Primary Debulking for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 145, 27-31. [Google Scholar] [CrossRef] [PubMed]
[10] 徐丽萍, 毛竹青, 陈爱平, 等. CT联合血清CA125水平评估卵巢癌行初次理想肿瘤细胞减灭术的临床价值[J]. 现代生物医学进展, 2018, 18(3): 537-540.
[11] Fagotti, A., Ferrandina, G., Fanfani, F., et al. (2006) A Laparoscopy-Based Score to Predict Surgical Outcome in Patients with Advanced Ovarian Carcinoma: A Pilot Study. Annals of Surgical Oncology, 13, 1156-1161. [Google Scholar] [CrossRef] 
[12] Saner, F.A.M., Ruggeri, G., Siegenthaler, F., Wampfler, J., Imboden, S. and Mueller, M.D. (2023) Change of Fagotti Score Is Associated with Outcome after Neoadjuvant Chem-otherapy for Ovarian Cancer. International Journal of Gynecological Cancer, 33, 1595-1601. [Google Scholar] [CrossRef] [PubMed]
[13] 张盛苗, 夏宝国, 楚蔚昕, 栾少红, 王丽, 聂小倩, 陈龙. 腹腔镜在晚期上皮性卵巢癌诊治中的价值[J]. 中国实用妇科与产科杂志, 2018, 34(1): 114-118.
[14] 郭融, 蔡钰峰, 王茂淮, 张慧娟. 血清学CA724、CA125检测联合ROMA值在卵巢癌诊断中的价值[J]. 国际检验医学杂志, 2020, 41(2): 168-171+175.
[15] Machida, H., Tokunaga, H., Matsuo, K., et al. (2020) Survival Outcome and Perioperative Complication Related to Neoadjuvant Chemotherapy with Carboplatin and Paclitaxel for Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis. European Journal of Surgical Oncology, 46, 868-875. [Google Scholar] [CrossRef] [PubMed]
[16] Mahdi, H., Maurer, K.A., Nutter, B., et al. (2015) The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients with Advanced-Stage Cancer of Mullerian Origin Treated with Neoadjuvant Chemotherapy. International Journal of Gyne-cological Cancer, 25, 823-829. [Google Scholar] [CrossRef] 
[17] Pelissier, A., Bonneau, C., Chéreau, E., et al. (2014) CA125 Kinetic Parameters Predict Optimal Cytoreduction in Patients with Advanced Epithelial Ovarian Cancer Treated with Neoadjuvant Chemotherapy. Gynecologic Oncology, 135, 542-546. [Google Scholar] [CrossRef] [PubMed]
[18] 李胜霞, 朱晨辰, 张安娜, 等. CA125动力学变化预测新辅助化疗晚期卵巢癌患者满意减瘤临床分析[J]. 现代妇产科进展, 2022, 31(10): 745-750.
[19] 刘超敏, 王涛. 卵巢癌的生物标志物CA125和HE4研究进展[J]. 甘肃医药, 2019, 38(5): 395-397.
[20] Baransi, S., Michaan, N., Gortzak-Uzan, L., et al. (2020) The Accuracy of Ascites Cytology in Diagnosis of Advanced Ovarian Cancer in Post-menopausal Women Prior to Neoadjuvant Chemotherapy. Menopause (New York, N.Y.), 27, 771-775. [Google Scholar] [CrossRef] 
[21] Wright, A.A., Bohlke, K., Armstrong, D.K., et al. (2016) Neoadjuvant Chemo-Therapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 3460-3473. [Google Scholar] [CrossRef] 
[22] Narasimhulu, D.M., Kumar, A., Weaver, A.L., et al. (2020) Less Guessing, More Evidence in Identifying Patients Least Fit for Cytoreductive Surgery in Advanced Ovarian Cancer: A Triage Algorithm to Individualize Surgical Management. Gynecologic Oncology, 157, 572-577. [Google Scholar] [CrossRef] [PubMed]
[23] Narasimhulu, D.M., Kumar, A., Weaver, A.L., et al. (2019) Using an Evidence-Based Triage Algorithm to Reduce 90-Day Mortality after Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 155, 58-62. [Google Scholar] [CrossRef] [PubMed]
[24] Mavaddat, N., Peock, S., Frost, D., et al. (2013) Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results from Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute, 105, 812-822. [Google Scholar] [CrossRef] [PubMed]
[25] Gorodnova, T., Sokolenko, A., Ni, V., et al. (2019) BRCA1-Associated and Sporadic Ovarian Carcinomas: Outcomes of Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy. In-ternational Journal of Gynecological Cancer, 29, 779-786. [Google Scholar] [CrossRef] [PubMed]
[26] Rauh-Hain, J.A., Nitschmann, C.C., Worley, M.J., et al. (2013) Platinum Resistance after Neoadjuvant Chemotherapy Compared to Primary Surgery in Patients with Advanced Epithelial Ovarian Carcinoma. Gynecologic Oncology, 129, 63-68. [Google Scholar] [CrossRef] [PubMed]
[27] 张杰. BRCA2关键结构域突变与卵巢癌新辅助化疗获得性铂类耐药的相关性研究[D]: [硕士学位论文]. 南宁: 广西医科大学, 2016.
[28] Zhang, G.N., Liu, H., Huang, J.M., et al. (2014) TP53 K351N Mutation-Associated Platinum Resistance after Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer. Gynecologic Oncology, 132(3): 752-757. [Google Scholar] [CrossRef] [PubMed]
[29] 张国楠, 朱熠, 黄建鸣. 紫杉醇在上皮性卵巢癌化疗中的双刃剑效应与对策思考[J]. 中国实用妇科与产科杂志, 2017, 33(1): 21-24.
[30] 成莉, 李琳, 邢辉. 首次肿瘤细胞减灭术与新辅助化疗后间隔性肿瘤细胞减灭术治疗III和IV期卵巢癌患者后其对铂类药物耐药性及生存期的影响[J]. 中国全科医学, 2014, 17(9): 1021-1025.
[31] Coleman, R.L., et al. (2017) Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 18, 779-791. [Google Scholar] [CrossRef] 
[32] 卢淮武, 林仲秋. 《2018NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南》解读[J]. 中国实用妇科与产科杂志, 2018, 34(5): 526-536.
[33] Li, N., Zhu, J., Yin, R., Wang, J., Pan, L., Kong, B., Zheng, H., Liu, J., Wu, X., Wang, L., Huang, Y., Wang, K., Zou, D., Zhao, H., Wang, C., Lu, W., Lin, A., Lou, G., Li, G., Qu, P., Yang, H., Zhang, Y., Cai, H., Pan, Y., Hao, M., Liu, Z., Cui, H., Yang, Y., Yao, S., Zhen, X., Hang, W., Hou, J., Wang, J. and Wu, L. (2023) Treatment with Niraparib Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 9, 1230-1237. [Google Scholar] [CrossRef] [PubMed]
[34] Harter, P., Mouret-Reynier, M.A., Pignata, S., Cropet, C., González-Martín, A., Bogner, G., Fujiwara, K., Vergote, I., Colombo, N., Nøttrup, TJ., Floquet, A., El-Balat, A., Scambia, G., Guerra Alia, E.M., Fabbro, M., Schmalfeldt, B., Hardy-Bessard, A.C., Runnebaum, I., Pujade-Lauraine, E. and Ray-Coquard, I. (2022) Efficacy of Maintenance Olaparib plus Bevacizumab According to Clinical Risk in Patients with Newly Diagnosed, Advanced Ovarian Cancer in the Phase III PAOLA-1/ENGOT-Ov25 Trial. Gynecologic Oncology, 164, 254-264. [Google Scholar] [CrossRef] [PubMed]
[35] Yoneoka, Y., Ishikawa, M., Uehara, T., Shimizu, H., Uno, M., Murakami, T. and Kato T. (2019) Treatment Strategies for Patients with Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: Interval Debulking Surgery or Additional Chemotherapy? Journal of Gynecologic Oncology, 30, e81. [Google Scholar] [CrossRef] [PubMed]
[36] Yao, S.E., Tripcony, L., Sanday, K., et al. (2020) Survival Outcomes after Delayed Cytoreduction Surgery Following Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 30, 1935-1942. [Google Scholar] [CrossRef] [PubMed]
[37] Stoeckle, E., Bourdarias, L., Guyon, F., et al. (2014) Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery. Annals of Surgical Oncology, 21, 629-636. [Google Scholar] [CrossRef] [PubMed]
[38] Kang, S. and Nam, B.H. (2009) Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies. Annals of Surgical Oncology, 16, 2315-2320. [Google Scholar] [CrossRef] [PubMed]
[39] Loizzi, V., Cormio, G., Resta, L., et al. (2005) Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Case- Control Study. International Journal of Gynecological Cancer, 15, 217-223. [Google Scholar] [CrossRef] [PubMed]
[40] Perrone, A.M., Coada, C.A., Ravegnini, G., De Leo, A., Damiano, G., De Crescenzo, E., Tesei, M., Di Costanzo, S., Genovesi, L., Rubino, D., Zamagni, C. and De Iaco, P. (2023) Post-Operative Residual Disease and Number of Cycles of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Carcinoma. International Journal of Gynecological Cancer, 33, 1270-1278. [Google Scholar] [CrossRef] [PubMed]
[41] Vergote, I., Tropé, C.G., Amant, F., et al. (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. The New England Journal of Medicine, 363, 943-953. [Google Scholar] [CrossRef] 
[42] Basaran, D., Boerner, T., Suhner, J., Sassine, D., Liu, Y., Grisham, R.N., Tew, W.P., Gardner, G.J., Zivanovic, O., Sonoda, Y., Long Roche, K., Chi, D.S., Abu-Rustum, N.R., Soff, G.A. and Jewell, E.L. (2021) Risk of Venous Thromboembolism in Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy. Gynecologic Oncology, 163, 36-40. [Google Scholar] [CrossRef] [PubMed]

为你推荐